Blood biomarkers-defined subgroups show heterogeneity in post-acute COVID-19 syndrome: a rationale for precision medicine.

- Benjamin Charvet¹, Alexandre Lucas², Justine Pierquin¹, Joanna Brunel¹, Steven Fried³,
 Corinne Bernis³, Zachary S. Orban³, Millenia Jimenez³, Barbara A. Hanson³, Lavanya
 Visvabharathy³, Igor J. Koralnik³, Hervé Perron^{1*}, PhD.
- ⁶ ¹Geneuro-Innovation, Bioparc Laennec, 69008, Lyon, France.
- 7^{2.} We-Met platform, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-
- 8 Met, Inserm UMR1297 and Université Paul Sabatier, Toulouse, France
- ³ Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago,
 IL, USA
- 11 * Correspondence: <u>hperron@geneuro.com</u>; Hervé Perron, Geneuro-Innovation, Bioparc Laënnec,
- 12 60A Avenue Rockefeller, 69008, Lyon, France. tel : +33 437 902 997
- 13 Keywords: long COVID-19, post-COVID-19, PASC, SARS-CoV-2, Immunoglobulin isotype,
- 14 HERV-W, TLR4, cytokine, neurofilament, cognitive symptoms, brain fog.
- 15 Word count: 2741.
- 16

17 Abstract

Acute COVID-19 can cause a post-infectious syndrome in a significant percentage of patients, with multifacted and long lasting symptoms. We hypothesized that this Post-Acute COVID syndrome (PASC) could result from various underlying causes, which may compromise the demonstration of efficacy for treatments evaluated on cohorts of heterogeneous patients.

22 To assess the feasibility of stratifying or characterizing subgroups of post-COVID-19 patients 23 consistent with different indications in a precision medicine perspective, we tested serum biomarkers 24 in a pilot cross-sectional study of patients with neuro-cognitive symptoms from the Northwestern 25 University post-COVID-19 clinic (Chicago,USA). Patient health status was evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive tests with the NIH Toolbox. 26 27 Serum biomarkers were chosen as proteins known to be involved in the pathogenic features of a 28 neuro-inflammatory disease, i.e., multiple sclerosis, with a final selection of the most discriminant 29 ones. A multi-isotypes serology against SARS-CoV-2 spike and nucleocapsid antigens was 30 performed to allow detailed analyses of the humoral immune status.

31 Despite the limited numbers of this feasibility study, results showed that clinical data could not 32 differentiate PASC patients with persisting neuro-cognitive impairment, while three major PASC 33 subgroups were identified with serum biomarkers according to the presence or absence of the HERV-34 W ENV soluble protein combined with neurofilaments light chains and, to a lesser extent, with 35 elevated levels of IL-6. SARS-CoV-2 serological results in PASC compared to healthy controls also 36 revealed a significant increase of anti-Spike and/or Nucleocapsid IgM, IgA and, unexpectedly, IgE. 37 For IgG, a significant difference was observed with Nucleocapsid only since anti-Spike IgG titers 38 were normally elevated in vaccinated controls. This multi-Ig isotypes serology may provide 39 additional information on the infectious and immunological status of individual patients and should 40 be considered in face of a potential viral persistence in some individuals.

41 Altogether the results show the feasibility of using serum biomarkers to discriminate relevant 42 subgroups or individual patients for precision medicine indications in post-COVID syndromes. This 43 pilot study paves the way to further exploring biological assays for the definition of subtypes of 44 DASC also be also be a subtype of the study paves the way to further exploring biological assays for the definition of subtypes of

44 PASC, also called long COVID, useful for the choice of relevant therapeutic strategies.

Introduction 46 1

47 The COVID-19 pandemic is now known to generate a post-viral syndrome with multifaceted and long-lasting symptoms, variably named "Long COVID", "Post-COVID" or "Post-Acute sequelae of 48 49 COVID-19 (PASC). Though the last denomination may suggest lingering post-infectious symptoms, e.g., ischemic tissue lesions following thrombotic events ¹, many symptoms appear to result from 50

ongoing pathogenic processes with possible onset of chronicity 2,3 . 51

52 In June 2022, the center for disease control (CDC) of the USA published that "more than 40% of adults in the United States reported having COVID-19 in the past, and nearly one in five of those 53 (19%) are currently still having symptoms of long COVID"⁴. In September 2022, the World Health 54 Organization (WHO) published that "at least 17 million people in the WHO European Region 55 56 experienced long COVID in the first two years of the pandemic; millions may have to live with it for years to come"⁵. The data points to a secondary pandemic caused by COVID-19, in the form of a 57 post-COVID syndrome of unknown duration and evolution with overlapping symptoms that may 58 result from various pathogenic factors and pathways⁶. In particular, persisting neurological and 59 cognitive symptoms appear common and affect the quality of life on the long term 7,8 . 60

61 Diagnosing and managing such a complex syndrome is a challenge that requires understanding how 62 to identify potentially differing mechanisms underlying the overlapping symptoms observed in these patients⁹. There is a need to identify markers which will differentiate between heterogeneous long-63 COVID subgroups and guide precision medicine where possible. For this purpose, we have selected 64 65 biomarkers from factors already known to be involved in COVID-19 and also suspected to contribute 66 to certain aspects of long COVID or PACS. We also focused on assays suitable for routine laboratory 67 analyses on serum samples, which can be easily obtained from patients.

68 In the present pilot study on patients from a post-COVID clinic presenting with persistent symptoms such as abnormal fatigue, sleep disorders and dominant neuro-cognitive symptoms, we have thus 69 70 studied (i) immunoglobulin isotypes of the humoral response against SARS-CoV-2 spike and 71 nucleocapsid antigens, (ii) the presence of an endogenous retroviral protein, HERV-W ENV, shown to be pathogenic for the immune and nervous systems ¹⁰⁻¹², with virus-induced expression ¹³⁻¹⁵ and 72 73 recently shown to predict disease severity when detected on lymphocytes from COVID-19 patients ¹⁶, (iii) the levels of major cytokines involved in COVID-19 inflammatory responses ¹⁷ and, because 74 75 of neuro-cognitive symptoms, (iv) the levels of neurofilament light chain (NfL) known to be accurate biomarkers of neuronal impairment even when quantified in the peripheral blood ¹⁸. 76

78 2 Methods

79 Participants and clinical assessment

80 This cross-sectional study was approved by the Northwestern University Institutional Review Board

81 (STU00215866). Blood collection from patients and sample processing followed standard operating

- 82 procedures with the appropriate approval of the Ethics and Scientific Committees (num.
- 83 20210604/04/02). Written informed consent was obtained from all study participants. Importation of
- 84 the human samples received the authorization IE-2022-2309 from the French ministry. Clinical and
- 85 demographic data from PASC patients are presented in **Table 1**. PASC patient health status was
- 86 evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive $\frac{819}{20}$
- 87 tests with the NIH Toolbox 8,19,20 .

88 Immunooassays

- 89 The detection of SARS-CoV-2 immunoglobulin isotypes (IgG, IgM, IgA and IgE) were performed
- 90 on serum by Simple Western technology (ProteinSimple/BioTechne, CA, USA) with manufacturer's
- 91 reagents according to their manual. HIS-tagged recombinant proteins of SARS-CoV-2 ((S)Spike, S1
- 92 Subunit, S2 Subunit, S1 RBD and Nucleocapsid were used to detect antibody responses to SARS-
- 93 CoV-2. The area under the curve (AUC) for the electrophoregram peak corresponding to the
- 94 immunodetection of each protein at the expected size was measured using Compass Software.

For the detection of HERV-W ENV antigen in serum analyses were also performed with simple western-Jess, according to the conditions provided in the patent "Method for the detection of the soluble hydrophilic oligomeric form of HERV-W envelope protein", published under ref. WO2019201908, with previously described sample treatment (32). The specific signal was expressed as the signal to noise (S/N) ratio, where the noise represents the mean+2SD of the background signals yielded by a panel of sera from healthy blood donors (EFS, Lyon-France). PASC samples were stored in freezers at -80°C for less than 6 months. All samples were kept frozen after their initial

- 102 freezing until use (no freeze/thaw cycle before the immunoassay).
- 103 Serum levels of NfL (# SPCKB-PS-002448) and IL-6 (# SPCKC-PS-006520) were quantified with
- 104 the fully automated immunoassay platform, Ella (ProteinSimple/Bio-techne, CA, USA). The lower
- 105 limits of quantification (LLOQ) were provided by the supplier as a threshold for normal baselines 3
- 106 pg/mL for IL-6. Age-standardized Z-scores were calculated for NfLs{Harp, 2022 #18599}. Serum
- 107 samples were run in triplicate and results in pg/mL were calculated by the instrument software
- 108 (SimplePlex Explorer, ProteinSimple/Bio-techne, USA).

109 *RT-qPCR*

- Total RNA was obtained from PAXgene tubes used to collect whole blood samples and stored at -20°C. RNA extraction used NucleoSpin RNA Mini Kit (Macherey Nagel, 740955) according to the manufacturer's protocol. 200 ng of DNase-treated RNA was reverse-transcribed into cDNA using iScript cDNA Synthesis Kit (Bio-Rad, 1708891) according to the manufacturer's protocol. A control with no-RT was used to confirm the absence of contaminating DNA. 5 ng of initial RNA in RT
- reaction was used in RT-qPCR for HERV-W *ENV*, HERV-W *POL*, HERV-K *ENV*, SARS-CoV-2 N
- genes. Primer sequences (5' to 3'): HERV-K ENV Forward CTGAGGCAATTGCAGGAGTT, Reverse
- 117 GCTGTCTCTTCGGAGCTGTT; HERV-W ENV Forward GTATGTCTGATGGGGGTGGAG,
- 118 Reverse CTAGTCCTTTGTAGGGGCTAGAG; HERV-W POL Forward CCTGTACGTCCTGACTCTC,
- 119 Reverse CTTGGGCTAATGCCTGGCC; SARS-CoV-2 N Forward AAACATTCCCACCAACAG,

120 Reverse CACTGCTCATGGATTGTT; B2M Forward TTACTCACGTCATTCAGCAG, Reverse 121 GATGGATGAAACCCAGACAC. Assays used StepOnePlus instrument (Applied Biosystems) with

122 Platinum SYBR Green (Invitrogen, 11744-500). Housekeeping gene beta-2 microglobulin (*B2M*) 123 normalized the results. A melting curve analysis confirmed the specificity of amplification and the

normalized the results. A melting curve analysis confirmed the specificity of amplification and the lack of non-specific products. Quantification used the threshold cycle (Ct) comparative method: the

124 lack of non-specific products. Quantification used the threshold cycle (Ct) comparative method: the 125 relative expression was calculated as follow: $2^{-[DCt (sample) - DCt (calibrator)]} = 2^{-DDCt}$, where DCt (sample) =

126 [Ct (target gene) – Ct (housekeeping gene)] and the DCt (calibrator) was the mean of DCt of healthy

127 controls.

128 Statistics

129 Statistical analyses were performed using Prism (version 9.0; GraphPad Software, La Jolla, 130 California). Continuous data are expressed as means $\Box \pm \Box$ SD, as indicated. Normal data distribution 131 was assessed using the Shapiro-Wilk or D'Agostino & Pearson's test, assuming p-values $\supset 0.05$. 132 Statistical differences were determined using Student's test (two tailed) for compared groups with 133 normal distributions, with Welch's correction when SDs of samples were significantly different (F 134 test p < 0.01) - Mann-Whitney U test (two tailed) was used for compared groups without normal 135 distribution and Wilcoxon signed rank test (two tailed) was used for comparison when a group only 136 or mostly comprised null or very low values for a given threshold. Chi-square (two tailed) test was 137 used for comparison of numbers in categories, replaced by Fischer's exact test when one category 138 had zero count. Correlation analyses were performed with Spearman test (two tailed). Statistical 139 significance was set at p < 0.05.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted April 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has costed April 3, 2023. The copyright holder for this preprint All rights reserved. No reuse allowed without permission.

141 3 **Results**

A total of 41 subjects (Table 1) were evaluated in this study. Controls (Ctrl) were caregivers or 142 143 volunteers from hospital (n=10) and PASC patients previously diagnosed with acute COVID-19 and 144 presenting with neuro-cognitive symptoms, (Neuro-PASC; n=31). These included 6 post-145 hospitalization Neuro-PASC (PNP) and 25 non-hospitalized Neuro-PASC (NNP) patients seen at 146 Northwestern Medicine Neuro-COVID-19 clinic.

147 **HERV-W ENV detection**

Following reports of HERV-W envelope RNA and protein in acute COVID-19 patients correlating 148 with disease severity and markers of T-cell exhaustion ¹⁶, this study analyzed HERV-W ENV RNA 149 150 from whole blood and levels of soluble envelope protein (W-ENV) in serum from PASC compared 151 to Ctrl. As shown in Figure 1 A-D, about one-half (11/23 with QC-passed RNA) of PASC 152 individuals had elevated RNA levels and about one-third (10/31) had detectable W-ENV protein in 153 serum, which was significantly different from Ctrl for both analyses (Wilcoxon Signed Rank test: 154 Ctrl W=1.00, PASC W=177.00, N=7+23, p=0.0055 for whole blood RNA, and Ctrl W=10.00, PASC 155 W=265.00, N=10+31, p=0.0020 for serum protein). RT-qPCR also detects non-coding RNA and it is 156 known that HERV RNA could play physiological roles as regulatory non-coding long or small RNA ^{21,22}. Nevertheless, the presence of circulating W-ENV protein, a potent TLR4 agonist, cannot be 157 neutral^{12,23-26}. 158

- 159 In Figure 1C PASC patients were stratified based on hospitalization status during acute SARS-CoV-2 160 infection. Positive cases for W-ENV protein represented about one fourth in the NNP subgroup 161 (24%, 6/25), but a majority in the PNP subgroup (67%, 4/6). The difference of W-ENV signal to 162 noise values (S/N) between NNP and controls was significant (Wilcoxon Signed Rank test: Ctrl 163 W=1.00, PASC W=21.00, N=10+25, p=0.0313) but, probably due to the low numbers, not between PNP and Ctrl. Interestingly, W-ENV positive (W-ENV+) PASC patients tended to be further from 164 165 the date of infection (Fig. 1D). A significant difference in the time from onset of acute COVID-19 166 between W-ENV+ and W-ENV- patients was confirmed (Unpaired t-test with Welch's correction: 167 t=2,346, df=17,61, N=21+10, p=0.0309). Some of these cases had suffered from post-COVID 168 symptoms for two years after the acute infection, which corresponded to the beginning of the 169 pandemic.
- 170

171 SARS-CoV-2 -specific antibody responses

- To study the humoral immune response to SARS-CoV-2 infection in PASC patients, we measured 172 the levels of all immunoglobulins (IgG, IgM, IgA and IgE) versus the control group (including 173
- 174 vaccinated individuals) against SARS-CoV-2 nucleocapsid (N) and spike (S) antigens.
- 175 Anti-N IgG were detected in a subgroup of PASC patients but not in controls (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC W=444.0, N=10+31, p<0.0001; Fig. 1E), whereas no difference with 176 177 Ctrl was observed for the anti-S IgG (Fig. 1F), which mostly indicated that Ctrl had been vaccinated 178 with this antigen. Comparing W-ENV positive and negative PASC patients showed that anti-N IgG 179 antibodies were detected in both subgroups, each one remaining significantly different from Ctrl (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC/W-ENV- W=193.0, N=10+21, p=0.0003; Ctrl 180 181 W=0.00, PASC/W-ENV+ W=53.0, N=10+10, p=0.0039; Fig. 1G), but no difference was seen
- 182 between PASC subgroups and Ctrl for anti-spike IgG (Fig. 1H).

183 As shown in Figure 2, IgM against both S and N proteins were only observed in a subgroup of PASC 184 patients with a wide range of titers. But, despite a few IgM positive PASC cases, a significant difference was seen versus controls for anti-N IgM (Wilcoxon Signed Rank test: Ctrl W=1600, 185 186 PASC W=476.0, N=10+31 p=0.0480; Fig. 2 A) and, with high significance, for anti-S IgM 187 (Wilcoxon Signed Rank test: Ctrl W=-6.00, PASC W=183.0, N=10+29, p<0.0001; Fig. 2 B). Of 188 note, two sera with non interpretable technical profiles were omitted.. IgA antibodies levels were 189 shown to be significantly elevated in PASC versus Ctrl for both N and S antigens, but anti-N IgA 190 better discriminated PASC versus Ctrl (Wilcoxon Signed Rank test: anti-N IgA, Ctrl W=16.00, 191 PASC W=476.0, N=10+31 p<0.0001; anti-S IgA, Ctrl W=-2.00, PASC W=273.0, N=10+31 192 p=0.0063; Fig. 2 C-D). Surprisingly, a subgroup of PASC patients had elevated IgE 193 immunoglobulins against both N and S antigens (Wilcoxon Signed Rank test: anti-N IgE, Ctrl 194 W=5.00, PASC W=336.0, N=10+31 p=0.0006; anti-S IgE, Ctrl W=14.00, PASC W=456.0, N=10+31 195 p<0.0001), with a large range of positivity versus all negative controls (Fig. 2 E-F).

196 *IL-6 quantification*

197 IL-6 was suggested to play a role in acute COVID-19 severity. In PASC, only a subgroup had 198 elevated IL-6 (about 35%, 11/31) but, whereas most values were below the normal threshold 199 (3pg/ml) in NNP, nearly all PNP (5/6) had elevated IL-6 levels in the serum with a significant 200 difference from Ctrl (Mann Whitney test: U=3, N=10+6, p=0.0017; Fig. 3A). When W-ENV positive 201 and negative PASC subgroups were compared, the W-ENV+ patients showed significantly higher IL-202 6 levels (Mann Whitney test: U=31, N=21+10, p=0.0011; Fig. 3B), consistently with the significant 203 correlation found between PASC serum levels of HERV-W ENV and IL-6 (Spearman correlation 204 test: r=0.5877, 95% CI 0.2847 to 0.7840, pairs N=31, p=0.0005; Fig. 3C). In figure 3D, PASC were 205 stratified according to both anti-N SARS-CoV-2 IgG and W-ENV serum levels. All samples from the 206 W-ENV+ subgroup had elevated IL-6 levels, when compared to all other W-ENV negative sera with 207 or without anti-N IgG (Mann Whitney test: W-ENV+/IgG N+ Vs W-ENV-/IgG N-, U=7, N=8+9, 208 p=0.0035; W-ENV+/IgG N+ Vs W-ENV-/IgG N+, U=10, N=8+13, p=0.0013; Fig. 3D).

209 Neuronal impairment biomarker: Neurofilament Light chain (NfL)

210 We measured the levels of serum NfL in PASC with cognitive impairment, since shown to be an

211 accurate peripheral biomarker of neuronal degeneration or injury within the central nervous system²⁷

212 (Figure 3E-G). Results were normalized with Z-score according to the age of the patients or control

213 individuals, as already defined 28 .

214 No significant difference was found between the distributions of NfL serum levels in PNP versus

- 215 NNP, nor Vs Ctrl (Fig. 3 E). Nonetheless, when stratified with W-ENV, all (100%, 10/10) W-ENV+
- 216 patients had elevated levels of serum NfL while only 62% (13 out of 21) of W-ENV-negative sera
- had a NFL Z-scores above 0 (Fisher exact test = 0.0317 p < 0.05, $\alpha = 1$, N=31; Fig. 3 F). Moreover, Z-
- scores were all above zero in the subgroup with both W-ENV and anti-N IgG positivity which was
- significantly different from the anti-N IgG+ and W-ENV- subgroup (Unpaired t test with Welch's

220 correction: t=2,688, df=17,61, N=22, p= 0,0152; Fig. 3G),.

221 Biomarker-defined subgroups

Figure 3H represents clusters of all PASC patients studied for the above-mentioned serum $\frac{222}{100}$ biometrics. Within the WENUL subgroup the majority (7/10) of DASC were positive alterestication for

- biomarkers. Within the W-ENV+ subgroup the majority (7/10) of PASC were positive altogether for
- NfL, IL-6 and IgG anti N-SARS-CoV-2 but only one (1/21) in the W-ENV negative subgroup (Chi-
- square statistic=17.890, p=0.00002, α =1, N=31 tested on all parameters). All W-ENV+ Neuro-PASC
- had positive serum levels of NfL (10/10). Moreover, within the W-ENV + subgroup, the NfL+
- 227 cluster included all IL-6+ or Ig anti-N+ sera and therefore coincided with W-ENV positivity in
- 228 Neuro-PASC patients, i.e., defined the same subgroup when combined with W-ENV positivity.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted April 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has construct the structure of the s

- 229 Matching with acute COVID effective hospitalization also, all HERV-W ENV+ patients from the 230 PNP subgroup were positive for the three other biomarkers (NfL, IL-6 and IgG anti-N; data not
- 230 11(1 suc
- 232 Within the W-ENV- subgroup, a single case was positive for NfL, IL-6 and IgG anti-N altogether. As
- found to be the core parameters in the W-ENV+ subgroup, this may question the sensitivity of the
- 234 present test for HERV-W ENV soluble antigen detection in serum. The patterns for single or double
- 235 positivity appeared to be variable while only NfLs positive levels were dominant, thereby suggesting
- 236 relationship with the neuro-cognitive impairment in this cohort. However, a cluster was clearly
- 237 identified to be negative for all these biomarkers, beyond negativity for W-ENV as well. This "all
- negative" cluster is consistent with very different pathogenic factors involved in their post-COVIDsymptomatology.
- 240 Of note, though all W-ENV+ patients had positive Z-scores for NfL, taken alone this biomarker
- revealed dominant in all Neuro-PASC cases, W-ENV+ and W-ENV- (Figure 3F). Negative Z-scores were found in few cases positive for IL-6 only or for IgG anti-N only but, most interestingly, within
- the isolated cluster negative for all tested biomarkers (figure 3H).
- SARS-CoV-2 serology showed significant differences with controls for anti-N IgG (Figure 1E) and for anti-N and/or anti-S IgM, IgA or IgE (Figures 2A-F). But, even in combination with other biomarkers, it did not provide a clear-cut stratification when considered without the other studied biomarkers.
- Therefore, Neuro-PASC subgroups could be defined as (i) W-ENV+ and NfL+, (ii) W-ENV- and (NfL+ or IL-6+ or IgG anti-N+) and (iii) negative for all the tested parameters. In addition, possible indication may be also provided on SARS-CoV-2 persistence by IgM, on the route of infection in extrapulmonary cases²⁹ or on the site of persistence by IgA and, particularly, on potentially associated immunoallergic symptoms by IgE.
- 253 Finally, using data from the PROMIS scale³⁰ and other clinical data showed no significant difference
- in the distribution of results between the subgroups consistently defined by the different biomarkers
- as exemplified with HERV-W ENV and anti-N-SARS-CoV-2 IgG in Figure 4.
- 256

257 Conclusion

258 The present results, despite the limited number of patients, consistently identified three major Neuro-259 PASC subgroups with significant differences stratified according to the presence or absence of the 260 HERV-W ENV protein combined with positive Z-score for NfLs in serum. SARS-CoV-2 serology 261 with all Ig isotypes should also provide useful indications on the infectious status, with possible viral 262 persistence or a possible immunoallergic specific phenotype linked to elevated anti-spike or 263 Nucleocapsid IgE. Since clinical data could not differentiate consistent subgroups of patients, unlike 264 biological parameters, the biomarker-defined subgroups or clusters may be considered for differing 265 therapeutic indications in post-COVID treatment. This should be a prerequisite for clinical trials to avoid mixing patients with and without the pathogenic target of a given drug, which may generate 266 267 non-significant results versus placebo, despite possibly responding cases. Thus, the presented biomarker and serology-based stratification should pave the way to precision medicine in post-acute 268 269 COVID sequalae or syndromes. Based on the present proof of concept and on that of other studies, a 270 diagnostic-based therapy with an anti-HERV-W ENV neutralizing antibody (Temelimab) is being 271 evaluated in a clinical trial with PASC patients positive for the HERV-W ENV protein in serum 272 (ClinicalTrials.gov Identifier: NCT05497089).

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted April 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has construct April 3, 2023. The copyright holder for this preprint All rights reserved. No reuse allowed without permission.

273 **Figure Legends**

274

275 Figure 1. HERV-W ENV and Anti-Nucleocapsid IgG antibody are significantly detected in PASC. A, HERV-W *ENV* mRNA detection in PBMCs based on change fold of $2^{-\Delta\Delta CT}$ compared to the mean of control groups; blue dots: 276 277 controls group; red dots: PASC group. Here, a lower number of samples was analyzed, since 8 PASC and 3 controls 278 yielded too low RNA concentration or did not pass QC (RIN<8). B, HERV-W ENV soluble oligomeric protein detection 279 in serum of patients, results are expressed on total signal normalized with the mean of background noise measured on 280 control cohort; blue dots : controls group; red dots : PASC group. C, post-hospitalized subgroup (PNP) is extracted from 281 the PASC group and compared to PASC subgroup not hospitalized during acute COVID-19 (NNP); blue dots: controls 282 group; red dots: NNP subgroup; dark red dots: PNP sub group. D, Comparison of the time from onset between HERV-W 283 ENV- and HERV-W ENV+ PASC subgroups; grey dots: PASC HERV-W ENV- subgroup; orange dots: PASC HERV-W 284 ENV+ subgroup. E, IgG anti-SARS-CoV-2 Nucleocapsid; F, IgG anti-SARS-CoV-2 Spike. Comparison between PASC 285 HERV-W ENV- and PASC HERV-W ENV+ subgroups for IgG anti-Nucleocapsid (G), and anti-Spike (H). The value on 286 the Y-axis (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the 287 immunodetected Ig isotype from tested sera against each antigen.

Figure 2. PASC serological IgM, IgA and IgE. A, IgM anti-SARS-CoV-2 Nucleocapsid; B, IgM anti-SARS-CoV-2 Spike IgM anti-S and N of two PASC patients with inconsistent results and diverging triplicate values were not be interpretable and therefore not taken into account in this analysis.; C, IgA anti-SARS-CoV-2 Nucleocapsid; D, IgA anti-SARS-CoV-2 Spike; E, IgE anti-SARS-CoV-2 Nucleocapsid and F, IgE anti-SARS-CoV-2 Spike. The value on Y axis (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig isotype from tested sera against each antigen.

294 Figure 3. Interleukine-6 (IL-6), neurofilament light chain (NfL) biomarkers and combination with HERV-W 295 ENV or anti-nucleocapsid IgG (IgG anti-N) status stratifying PASC patients. A, IL-6 dosages for controls (bleu 296 dots), NNP (red dots) and PNP (dark red dots). B, IL-6 dosage comparisons between HERV-W ENV- and HERV-W 297 ENV+ subgroups in PASC cohort. C, correlation between IL-6 and HERV-W ENV levels in serum. D, IL-6 levels in 298 PASC patients stratified by: HERV-W ENV- / IgG anti-N- (grev dots), HERV-W ENV- / IgG anti-N+ (blue dots) and 299 HERV-W ENV+ / IgG anti-N+ (red dots). E, NfL Z-Scores of controls (blue dots), NNP (red dots) and PNP (dark red 300 dots). NfL Z-scores comparisons between HERV-W ENV- and HERV-W ENV+ subgroups in PASC cohort. G, NfL 301 levels in different PASC subgroups: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) 302 and HERV-W ENV+ / IgG anti-N+ (red dots). H, Graphical presentation of patients' clusters defined by the selected 303 serum biomarkers, within HERV-W ENV negative and HERV-W ENV positive subgroups. The sera positive for each 304 biomarker are represented by dots in the colored circles; those negative for all parameters are in the grey oval.

Figure 4. Comparison of clinical data between groups based on HERV-W ENV and serology profiles. Three
groups from the PASC cohort are represented based on main biomarkers results: HERV-W ENV+ /Igs anti-SARS-CoV-2
Nucleocapsid (Ig anti-N) + ; HERV-W ENV- /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N) + and HERV-W ENV/Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N). Several parameters were studied: A, Processing speed; B, Attention; C,
Executive function; D, Working Memory; E, Cognitive function; F, Fatigue; G, Anxiety; H, Depression and I, Recovery
compared to the baseline.

312 **Conflict of Interest**

313 *HP*, *BC*, *JB* and *BC* receive compensation from Geneuro-Innovation for their work. The other 314 authors declare that the research was conducted in the absence of any commercial or financial 315 relationships that could be construed as a potential conflict of interest.

316

317 Author Contributions

- 318 IK : conceptualization of the study, evaluating all patients in the Neuro-COVID-19 clinic,
- 319 supervising patients sample collection, manuscript editing and review
- NW collaborators: Zack and Millenia: organized sample and data collection from all Neuro-PASC
 and control patients at Northwestern University, manuscript review
- 322 Barbara and Lavanya: Conceptualization of the study, assisted in sample and data collection from all
- 323 Neuro-PASC and control patients at Northwestern University, editing and reviewing the manuscript
- HP: conceptualization, supervision, formal analysis, investigation, data curation, writing and manuscript review.
- AL, CB, SF: HERV-W-ENV detection, NfL, cytokines HERV-W-ENV detection, NfL, cytokines,
 serological analyses.
- 328 B.C.: methodology, management interpretation of analyses and manuscript review.
- 329 J.P: Serological and antigenemia analyses; graphs, figures drawing and manuscript review.
- 330 J.B.: PCR, serological and antigenemia analyses; graphs, figures drawing and manuscript review.

H.P. and E.O.: conceptualization, funding acquisition, supervision, formal analysis, investigation,
 data curation, writing original draft and manuscript review.

- 333 All authors contributed to the article and approved the submitted version.
- 334
- 335

336 **References**

337

Hamouda D, Jillella DV, Bhatt N, Koneru S, Frankel MR, Nogueira RG. Intraluminal carotid
 thrombosis and acute ischemic stroke associated with COVID-19. *J Neurol*. Dec 2021;268(12):4443 4447. doi:10.1007/s00415-021-10562-1

Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathyassociated morbidity in Covid-19 patients. *Ann Clin Transl Neurol*. Nov 2020;7(11):2221-2230.
doi:10.1002/acn3.51210

344 3. Nehme M, Braillard O, Chappuis F, CoviCare Study T, Guessous I. The chronification of
post-COVID condition associated with neurocognitive symptoms, functional impairment and
increased healthcare utilization. *Sci Rep.* Aug 25 2022;12(1):14505. doi:10.1038/s41598-022-18673z

- 348 4. CDC. Prevalence of long COVID in the USA. 2022.
- 349 5. WHO. Long COVID in the WHO European Region. 2022.

Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated Global
Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters
Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. Oct 25 2022;328(16):1604-1615.
doi:10.1001/jama.2022.18931

Ali ST, Kang AK, Patel TR, et al. Evolution of neurologic symptoms in non-hospitalized
 COVID-19 "long haulers". *Ann Clin Transl Neurol*. Jul 2022;9(7):950-961. doi:10.1002/acn3.51570

356 8. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive
357 dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol. May
358 2021;8(5):1073-1085. doi:10.1002/acn3.51350

9. O'Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and Challenges of the Clinical
Diagnosis and Management of Long COVID. *JAMA Netw Open*. Nov 1 2022;5(11):e2240332.
doi:10.1001/jamanetworkopen.2022.40332

Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein
of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and
promotes Th1-like responses. *J Immunol*. Jun 15 2006;176(12):7636-44.

Firouzi R, Rolland A, Michel M, et al. Multiple sclerosis-associated retrovirus particles cause
T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J *Neurovirol.* Feb 2003;9(1):79-93. doi:10.1080/13550280390173328

368 MN2N2T34QVXHRWNY [pii]

Kremer D, Gruchot J, Weyers V, et al. pHERV-W envelope protein fuels microglial celldependent damage of myelinated axons in multiple sclerosis. *Proc Natl Acad Sci U S A*. Jul 23
2019;116(30):15216-15225. doi:10.1073/pnas.1901283116

372 13. Ruprecht K, Obojes K, Wengel V, et al. Regulation of human endogenous retrovirus W
373 protein expression by herpes simplex virus type 1: implications for multiple sclerosis. *J Neurovirol*.
374 Feb 2006;12(1):65-71. doi:T6G5G8M106986441 [pii]

375 10.1080/13550280600614973

- 14. Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of
 Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus6A and CD46 Receptor Engagement. *Front Immunol.* 2018;9:2803. doi:10.3389/fimmu.2018.02803
- Li F, Nellaker C, Sabunciyan S, et al. Transcriptional derepression of the ERVWE1 locus
 following influenza A virus infection. *J Virol*. Apr 2014;88(8):4328-37. doi:10.1128/JVI.03628-13
- Balestrieri E, Minutolo A, Petrone V, et al. Evidence of the pathogenic HERV-W envelope
 expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.
 EBioMedicine. Apr 2021;66:103341. doi:10.1016/j.ebiom.2021.103341
- 17. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV2. *Nat Immunol*. Feb 2022;23(2):165-176. doi:10.1038/s41590-021-01091-0
- Fisse AL, Pitarokoili K, Leppert D, et al. Serum neurofilament light chain as outcome marker
 for intensive care unit patients. *J Neurol*. Apr 2021;268(4):1323-1329. doi:10.1007/s00415-02010277-9
- Lai JS, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two
 sides of one coin? *Psychooncology*. Oct 2014;23(10):1133-41. doi:10.1002/pon.3522
- 20. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence
 measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys Med Rehabil.* Oct 2011;92(10 Suppl):S20-7. doi:10.1016/j.apmr.2010.08.033
- Wilson KD, Ameen M, Guo H, et al. Endogenous Retrovirus-Derived lncRNA BANCR
 Promotes Cardiomyocyte Migration in Humans and Non-human Primates. *Dev Cell*. Sep 28
 2020;54(6):694-709 e9. doi:10.1016/j.devcel.2020.07.006
- 397 22. Chishima T, Iwakiri J, Hamada M. Identification of Transposable Elements Contributing to 398 **Tissue-Specific** Expression of Long Non-Coding RNAs. Genes (Basel). Jan 9 399 2018;9(1)doi:10.3390/genes9010023
- 400 23. Johansson EM, Bouchet D, Tamouza R, et al. Human endogenous retroviral protein triggers
 401 deficit in glutamate synapse maturation and behaviors associated with psychosis. *Science Advances*.
 402 2020;6(29):eabc0708. doi:10.1126/sciadv.abc0708
- 403 24. Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSRV envelope protein is a 404 potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in 405 multiple sclerosis treatment. JNeuroimmunol. Feb 15 2016;291:29-38. doi:10.1016/j.jneuroim.2015.12.006 406
- 407 25. Duperray A, Barbe D, Raguenez G, et al. Inflammatory response of endothelial cells to a
 408 human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. *Int Immunol*.
 409 Nov 2015;27(11):545-53. doi:10.1093/intimm/dxv025
- 410 26. Kremer D, Schichel T, Forster M, et al. Human endogenous retrovirus type W envelope
 411 protein inhibits oligodendroglial precursor cell differentiation. *Ann Neurol.* Nov 2013;74(5):721-32.
 412 doi:10.1002/ana.23970
- 27. Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with
 10-year MRI outcomes in multiple sclerosis. *Ann Clin Transl Neurol*. Dec 2018;5(12):1478-1491.
 doi:10.1002/acn3.638
- 416 28. Harp C, Thanei GA, Jia X, et al. Development of an age-adjusted model for blood 417 neurofilament light chain. *Ann Clin Transl Neurol*. Apr 2022;9(4):444-453. doi:10.1002/acn3.51524

- 418 29. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat* 419 *Med.* Jul 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3
- 420 30. Vartanian K, Fish D, Gronowski B, Kenton N, Robicsek A. Patient-Reported Outcomes for
- 421 Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough
- 422 Cases. Patient. Nov 7 2022:1-12. doi:10.1007/s40271-022-00605-8



medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted April 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Igs anti-SARS-Covi-2 - Spike





Figure 3

IgG anti-N



Trop.	Page 1		PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	PASC	9	9	9	9 1			9	P	۹	ginang		
appeal and	Tende	Male	Male	Female		Rxi		rep /as	rint	t do	intif	ttps ied	<mark>≣/</mark> e	per				on l	20 the	13.	og. tho	si r/fu		2 <mark>88</mark> er.	<mark>oo:</mark> wh	s th		ver	sio	n p	ost	ed A Rxi	pri	3, lice	202 nse	3. to	he	cop	yrig the	ht holder for	this percet	preprint
8-8		20-CC	65-70	69-55	20-25	40-65	55-60	25-30	30-35	40-45	25-30	15-20	25-30	69-55	50-B	5-5	15-40	E C	ght B	Sci	ese E	ER C	08-5 0	9-59	10-B	Se -30	allo	we	65	Soler Soler	Q.ut	ge		sio	10-13 13-13	106	10-5	55-60	25-30	Å2	aphics	
211	H R		33		31	410	358	346	MS	203	274	26	Ħ	305	EM	260	342	Ħ	152	112	SEC	27	362	211S	2000	SEC	209	Unknown	10C	787	413	324	88		242	344	121	35	316	Days from list		
560	100		1		32D	133	336	15	127	162	243	12	319	8	12		207	11	TEZ	199	214		241	94	199	214	188	Unknown	171	258	392	BIE	181	i R	50	32	193	331	294	Days from 2nd vaccine		
-22	10	g				88	44			75			97				ы		32							26		40			111	105	8	75				85	4	Days from 3nd		
FL4	TUSIONE	Ra	Positive	Negative	Positive	Positive	Positive	Positive	EU	Positive	Positive	ma	na	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	POSIDIVE	Positive	Negative	Negative	Negative	Versive	Negative	Negative	Negative	Negative	Negative	SHRS- Colv-2 RT PCR results	Dimical da	
Rd.	1	: 2	R	8	R	Ell	EU	Eu	Positive	B	R	Positive	B	B	R	R	R	Ell	22	E U	R	R	EU	EU	EU	R	R	R	R	EU										SARS- CoV-2 Antigen test		
- 112	UCI I		516	524	341	496	88	202	44	176	444	711	316	AS1	360	815	1.LE	282	606	371	88	EME	88	541	SEE	605	372	443	*	EGE										Days from acute onset		
Cal	1	t d	Yes	6	No	No	No	No	No	No	No	No	No	6	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	Yes	No				Ĵ		10	No	6	No	hospita- lized for COVID- 19?		
24	a 1	6 0																	s										09											Days hospilta- lined		
Cal	1	t d	les	6	8	No	No	No	No	No	No	6	10	6	10	6	No	N	No	No	6	8	Yes	No	No	No	No	5	Yes	Yes					-20	8	6	6	No	preumo- nia?		
30	F 8	i di	6	6	No	No	No	No	No	No	No	8	10	8	6	No	No	No	Ĭß	No	6	No	No	No	No	10	No	6	in the second se	No						8	6	6	No	by posial	1	
n.a	: 0	t No	-														24.00		No										10											innula- and?	1	
100	Fd	10	Unknown																10										les											encepha- lopathy		
Call	f d	f Ø	Ē	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1¢	Yes	Yes	Ves	Yes	Yes	Yes	Yes	Yes	Ves	10	Yes										Braim Fog		
10	5 8	i di	Í Ø	Yes	(R	Yes	YB	YR	YB	(B	Yes	YB	ŤR.	6	10R	(R	18	YB.	(R	Y B	ŤR.	(R	YR	YB	YB	YB.	YB	(R	(R	Yes										atigue A	M	
8	F 8	5 8	fes	Yes	8	Yes	Yes	6	No	Yes	8	Yes	8	1 B	Yes	8	8	Yes	Nes	Yes	Yes	Yes	Yes	No	Yes	6	Yes	8	Yes	Yes										nomia -	obgicals	
ON	e a	NO	R.	109	No	NR NR	Yes.	No	No	No	No	No	No	Ŕ	1	109	No	10R	10R	Ŕ	18	N.	No.	No	19	No	N/R	No	08	19										0) gensia	Indians	
ī	10	1 0	6	6	10	YB	M	Yes	No	YB	No	Ye	YR	Ň	YR	6	No	N	Yes	YR	YB	10	No	Ye	Yes	Y BR	YB	6	Yes	Yes			Τ		T	T				Depressi Anxiet		ĺ
8	8 8	98 B	a bi	8	3	6	8	R.	90		8	œ	8	8	8	ы	۲ ۲	8		54	19	10	0	6	ũ.	ĸ	Œ	10		8	10	112	10	2	12	nz	nz	n	14	on % recove		ļ
1					10	-	1	10	10	10	10	10	1			Last .	test.	10	2		52	2	1	-		-	- 24	10	1-1	4		Netz	-				12	7		and Spee	0.0	
					1								<u> </u>	<u> </u>	-			1	1	200		1				0					() s	Line Ne	-				2	2	1	a Ta		
1	2 1	11 19	8 8	8	5	2	85	105	8	\$4	4	21	85	4	E	-	æ	85	E	51	12	W.	Œ	漢	ñ	65	9	4	1	R.	12	prine N	R	2	2 2	12	nz.	R	n.	cone Fu	Toolbox	
5	8 1	5 U	: 23	12	11	34	69	11 11	47	55	13	lat.	22	69	4	22		45	16	40	85	1L I	E	Δ£	63	56	II	41	10	43	11.0	gzite No	n.e	n	1.0	1.2	11.0	na	n.a	ecutiv e action T-	17	
2	C 2	8 0	8	\$	12	15	46	3E	02	0f	ts.	4	48	83	60	-	20	9E	6E	5	10	17	4	12	15	53	49	13	10	35	210	gatine W	12	2	1	12	12	12	20	score 1		
12	1	1/21	50	-	12	45	38,1	40	40	ń.	H	e	-	10	12	#	10	49	110	10	45	255	45	19	15	эř.	34	151	*	H	R.I	gane	R.R.	n 1	11	0.2	1.2	1,2	1.1	gnitive ction T- core		
NUCCES	Underse	and and and	Normal	Normal	Nodeste	Mill	Nodeste	PEN	NH.	Nodezie	Nodeste	Mild	Noderate	Noderate	Nodeste	REN	Nodesta	Normal	Noderate	Noderate	Normal	Nodezia	RN	Senare	Noderate	Nodeste	Nedeztz	Nodaziz	Nodersta	Nodeste	nz	Regian	R.	2 1	2 2	2	12	đ	2	Enginitive Function Category		
cto	240	2 2	: 10	19	74	2	82	88	52	30	55	192	8	Si l	60	8	8	54	828	35	12	617	8	11	20	34	55	52	11	15	2.0	Ngane	72	201	2	1.2	R	72	14	Fatigue T-score		
WILLIAGE .	Labora .	NUMPER	MN	Mild	Severe	Nederate	RN	Noderate	RM	Severe	RIN	Mak	Nederate	Moderate	RM	Notista	Nederate	Noderate.	Moderate	Sentre	Normal	Noderate	Nederate.	Severe	Noderate	Severe	Nederate	NIH	Sevene	RN	n.¢	Ngilie	8.4	nz	P.2	R.2	1.2	8.0	1.2	Fatigue Category		
470	101	a/co	46	5	12	55	#	12	85	52	55	35	60	53	80	53	49	85	TIS	595	22	505	15	M	10	10	13	5	10	15	2.0	Ngaine	2.0	1.0	1.2	1,2	211.	7.2	n.a	Anxiety T-Score		
NUCCIAL	the state of the s	NUCCIAL	Normal	Normal	Noderate	Noderate	Normal	Moderate	Mid	Mid	Moderate	PBN	Mid	Moderate	Mid	Noderate	Normal	PBN	Seree	Moderate	Noderate	Noderate	PBN	Same	Moderate	Noderate	Moderate	Normal	Mid	Moderate	11	Ngaire	R	2	2	na	12	R	112	Anxiety . Gategony	NOM15	
612.0	22	ere	42	8	25	12	48	51	- 57	22	11	499	55	52	48	52	4	42	573	CI3.	53	115	47	60	22	10	22	45	14	54	1.1	Ngzite	1.1	2	1.2	8,2	2.11	1.1	0.0)epression T-Score		
and and and	the state	an a	Normal	Normal	Nonul	Nederate	Normal	Normal	NE	MEN	RN	Norral	Normal	RN	Normal	Mederate	Nonul	Normal	Moderate	Moderate	Nemal	Normal	Nonul	Severe	Normal	Moderate	PEN	Normal	Normal	Normal	1.1	Negative	7,2	201	n.2	R.2	2.0	1.1	1.1	Depressio		
-	a :		8 68	-	R		46,3	1	5	R	in	45,4	10	2	8	B	in	-	61,4	10	B	122	8	8	8	1	R	ы	T	-	ne-	Negative	11	1	11	N	10	11	5.0	Seep Disauchar T-Score		
0.00				Non	5	Node	Nor	Non	M	Node	Non	Non	Nom	Node	Mode	Noda	Non	Node	Node	Node	Node	Noda	15	M	Node	Node	Node	15	S. S.	Node	10	Nega	E I	2	2 2		z	P	E	Sie Dishuri Categ	3	
-		0	0.	pu	0.	alt	p.	F	a	ate.	in the	a.	-	記録	ali	ale.	The state	alt	alle.	alle .	ale	ate.		n	ate.	all fr	ale	n.	10	alt		ine					1			au A Bauce Ba	0 0	